stockrowReplimune Group, Inc.
REPL- EPS
- +39.7%
- Free cash flow
- +42.2%
- Total debt
- +74.3%
Quarter to September 2026, against a year earlier
Follow REPL
Alert me
Replimune Group, Inc. (REPL) Return on invested capital
Replimune Group, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −928.3%, up 7108.3 percentage points from fiscal 2026 (−8,036.6%). Over the past ten years it has ranged from −14,281.0% (fiscal 2025) to 0.00% (fiscal 2018); the current reading is higher than 20% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2026 | −8,036.6% | 6,244.40 |
| FY2025 | −14,281.0% | (13,615.77) |
| FY2024 | −665.2% | (213.80) |
| FY2023 | −451.4% | (266.42) |
| FY2022 | −185.0% | (79.02) |
| FY2021 | −105.9% | (35.60) |
| FY2020 | −70.3% | 131.01 |
| FY2019 | −201.4% | (201.35) |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | 43.0% |
| ZYME Zymeworks Inc. compare | 17.5% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.00% |
| IMNM Immunome, Inc. compare | 0.00% |
| VERA Vera Therapeutics, Inc. compare | 0.00% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| VIR Vir Biotechnology, Inc. compare | −30.3% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −88.5% |
| REPL Replimune Group, Inc. | −928.3% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)